Küçük NÖ - Search Results

1

Negative Histopathological Prognostic Factors Affecting Morbidity in T1 Differentiated Thyroid Carcinoma.

Araz M, Özkan E, Gunduz P, Soydal C, Küçük NÖ, Kır KM. Araz M, et al. Among authors: kucuk no. Cancer Biother Radiopharm. 2022 Feb;37(1):56-62. doi: 10.1089/cbr.2020.4679. Epub 2021 Sep 15. Cancer Biother Radiopharm. 2022. PMID: 34524012

2

False-positive results obtained with stress myocardial SPECT in patients with right bundle branch block.

Küçük NO, Arican P, Ibiş E, Aras G, Berkalp B, Oral D, Kir KM. Küçük NO, et al. Clin Nucl Med. 2000 Aug;25(8):585-7. doi: 10.1097/00003072-200008000-00002. Clin Nucl Med. 2000. PMID: 10944010

3

Evaluation of persistent edema with lymphoscintigraphy after femoral artery injury.

Küçük NO, Gülev B, Aras G, Kir KM. Küçük NO, et al. Clin Nucl Med. 2002 Mar;27(3):227-8. doi: 10.1097/00003072-200203000-00025. Clin Nucl Med. 2002. PMID: 11852323 No abstract available.

4

A hypophyseal metastasis of follicular thyroid carcinoma.

Küçük NO, Arícan P, Aras G, Kír KM. Küçük NO, et al. Clin Nucl Med. 2002 Apr;27(4):309-10. doi: 10.1097/00003072-200204000-00022. Clin Nucl Med. 2002. PMID: 11914682 No abstract available.

5

Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results.

Küçük NO, Külak HA, Aras G. Küçük NO, et al. Ann Nucl Med. 2006 Jul;20(6):393-7. doi: 10.1007/BF03027374. Ann Nucl Med. 2006. PMID: 16922467

6

Treatment for microcarcinoma of the thyroid--clinical experience.

Küçük NO, Tari P, Tokmak E, Aras G. Küçük NO, et al. Clin Nucl Med. 2007 Apr;32(4):279-81. doi: 10.1097/01.rlu.0000257272.90126.3d. Clin Nucl Med. 2007. PMID: 17413573

7

Uncommon extent involvement of sarcoidosis in 18F-FDG PET/CT.

Küçük NO, Ozkan E, Aras G. Küçük NO, et al. Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2151. doi: 10.1007/s00259-007-0555-6. Epub 2007 Sep 14. Eur J Nucl Med Mol Imaging. 2007. PMID: 17874096 No abstract available.

8

Is thyroglobulin the stronger indicator for progressive disease than the other conventional factors in same age patient groups with differentiated thyroid cancer?

Aras G, Gültekin SS, Küçük NO, Genç Y. Aras G, et al. Among authors: kucuk no. Nucl Med Commun. 2007 Dec;28(12):907-13. doi: 10.1097/MNM.0b013e3282f1ac6c. Nucl Med Commun. 2007. PMID: 18090216

9

The additive clinical value of combined thyroglobulin and antithyroglobulin antibody measurements to define persistent and recurrent disease in patients with differentiated thyroid cancer.

Aras G, Gültekin SS, Küçük NO. Aras G, et al. Among authors: kucuk no. Nucl Med Commun. 2008 Oct;29(10):880-4. doi: 10.1097/MNM.0b013e328308e079. Nucl Med Commun. 2008. PMID: 18769305

10

Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.

Ozkan E, Tokmak E, Kucuk NO. Ozkan E, et al. Among authors: kucuk no. Ann Nucl Med. 2011 Jul;25(6):425-31. doi: 10.1007/s12149-011-0482-2. Epub 2011 Apr 8. Ann Nucl Med. 2011. PMID: 21476058

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

65 results

Search Page